TY - JOUR
T1 - Redefining and measuring transplant conditioning intensity in current era
T2 - a study in acute myeloid leukemia patients
AU - Spyridonidis, Alexandros
AU - Labopin, Myriam
AU - Savani, Bipin N.
AU - Niittyvuopio, Riitta
AU - Blaise, Didier
AU - Craddock, Charles
AU - Socié, Gerard
AU - Platzbecker, Uwe
AU - Beelen, Dietrich
AU - Milpied, Noel
AU - Cornelissen, Jan J.
AU - Ganser, Arnold
AU - Huynh, Anne
AU - Griskevicius, Laimonas
AU - Giebel, Sebastian
AU - Aljurf, Mahmoud
AU - Brissot, Eolia
AU - Malard, Florent
AU - Esteve, Jordi
AU - Peric, Zinaida
AU - Baron, Frédéric
AU - Ruggeri, Annalisa
AU - Schmid, Christoph
AU - Gilleece, Maria
AU - Gorin, Norbert Claude
AU - Lanza, Francesco
AU - Shouval, Roni
AU - Versluis, Jurjen
AU - Bug, Gesine
AU - Fløisand, Yngvar
AU - Ciceri, Fabio
AU - Sanz, Jamie
AU - Bazarbachi, Ali
AU - Nagler, Arnon
AU - Mohty, Mohamad
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - To address limitations of the currently used reduced-intensity/myeloablative conditioning (RIC/MAC) classification scheme we aimed to develop a tool that can capture more standardized the conditioning intensity of allogeneic hematopoietic cell transplantation (HCT). We assigned intensity weight scores for frequently used conditioning regimen components and used their sum to generate the transplant conditioning intensity (TCI) score. We retrospectively tested the impact of TCI on 8255 adult (45–65 years) acute myeloid leukemia patients who underwent HCT in first complete remission. A Cox model for early nonrelapse mortality (NRM) yielded a 3-group TCI risk scheme (low, intermediate, high) with respective TCI scores of [1–2], [2.5–3.5] and [4–6]. On multivariate modeling, TCI grouping was highly and better predictive for early (day 100 and 180) NRM, 2-year NRM and relapse (REL) as compared with the RIC/MAC classification. Validation was done on 200 bootstrap samples. Moreover, TCI scoring enabled the identification of a distinct subgroup of RIC and MAC conditioning regimens with an intermediate TCI [2.5–3.5] score that had identical outcomes and which are frequently referred as “reduced toxicity conditioning”. TCI scheme provides an improvement of the RIC/MAC classification. We propose TCI as a new tool to define and measure the conditioning regimen intensity.
AB - To address limitations of the currently used reduced-intensity/myeloablative conditioning (RIC/MAC) classification scheme we aimed to develop a tool that can capture more standardized the conditioning intensity of allogeneic hematopoietic cell transplantation (HCT). We assigned intensity weight scores for frequently used conditioning regimen components and used their sum to generate the transplant conditioning intensity (TCI) score. We retrospectively tested the impact of TCI on 8255 adult (45–65 years) acute myeloid leukemia patients who underwent HCT in first complete remission. A Cox model for early nonrelapse mortality (NRM) yielded a 3-group TCI risk scheme (low, intermediate, high) with respective TCI scores of [1–2], [2.5–3.5] and [4–6]. On multivariate modeling, TCI grouping was highly and better predictive for early (day 100 and 180) NRM, 2-year NRM and relapse (REL) as compared with the RIC/MAC classification. Validation was done on 200 bootstrap samples. Moreover, TCI scoring enabled the identification of a distinct subgroup of RIC and MAC conditioning regimens with an intermediate TCI [2.5–3.5] score that had identical outcomes and which are frequently referred as “reduced toxicity conditioning”. TCI scheme provides an improvement of the RIC/MAC classification. We propose TCI as a new tool to define and measure the conditioning regimen intensity.
UR - http://www.scopus.com/inward/record.url?scp=85078668287&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-0803-y
DO - 10.1038/s41409-020-0803-y
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31996792
AN - SCOPUS:85078668287
SN - 0268-3369
VL - 55
SP - 1114
EP - 1125
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 6
ER -